#United States #Los Angeles #Securities Fraud #GeneDx Holdings #NASDAQ WGS

GeneDx Holdings Corp. Investor Alert

GeneDx Holdings Corp. is currently under scrutiny as a national shareholder rights litigation firm, Schall Brown & Schwartz LLP, has announced a class action lawsuit against it for potential violations of securities laws. This comes as a significant concern for investors who purchased GeneDx securities during the specified class period from April 16, 2025, to May 4, 2026.

The firm is reminding investors that they have until August 3, 2026, to join the lawsuit, which has implications under §§10(b) and 20(a) of the Securities Exchange Act of 1934, specifically concerning Rule 10b-5. This rule is crucial as it addresses the prohibition of false or misleading statements and fraudulent activities in the sale of securities.

Background of the Class Action

The catalyst for this situation arose after GeneDx’s Q1 2026 financial results announcement on May 4, 2026. The results showed a significant drop in the company's adjusted gross margin and a lowered earnings projection. Additionally, the company recognized a massive $31.3 million impairment related to its Fabric Genomics unit. This revelation appeared to directly contravene earlier statements made by GeneDx, which were deemed false and misleading throughout the class period, leading to substantial losses for investors.

Schall Brown & Schwartz LLP is encouraging shareholders who suffered losses during this period to consider joining the lawsuit. Notably, becoming a lead plaintiff, which involves taking an active role in directing the lawsuit on behalf of other class members, is not a requirement for recovering losses.

The firm highlighted that potential claimants can participate in the lawsuit without facing any out-of-pocket costs, creating an avenue for those impacted to seek compensation for their financial setbacks.

Steps for Investors

If you acquired shares of GeneDx Holdings Corp. (NASDAQ: WGS) during the class period, it is imperative to act promptly. Interested parties are advised to reach out to Brian Schall and David Schwartz at the firm, where initial consultations are available without any charge. The firm is reaching out to those potentially eligible to recover their losses during this tumultuous period.

For those who choose not to take any action, they will remain absent class members until further developments occur regarding the certification of the class. As of now, the class has not yet been certified, meaning investors are not currently represented by legal counsel unless they act.

The Reputation of SBS

Schall Brown & Schwartz LLP prides itself on its extensive experience in representing investors worldwide, focusing specifically on securities class action lawsuits and shareholder rights litigation. The founding partners—Brian Schall, Andrew Brown, and David Schwartz—bring a wealth of knowledge and success, having recovered over a billion dollars for clients affected by violations of securities laws and corporate malfeasance.

This situation serves as a critical reminder of the importance of maintaining vigilance regarding company disclosures and the rights of investors. The GeneDx Holdings case underscores the need for stakeholders to remain proactive in understanding their rights, especially in turbulent market conditions.

For more information, or to determine if you are eligible to join this class action lawsuit, reach out to Schall Brown & Schwartz LLP at their Los Angeles office by phone or through their official website.

In conclusion, for the investors of GeneDx Holdings Corp., the time to act is now. With a looming deadline and the possibility of compensation on the horizon, every eligible investor should evaluate their options regarding this significant legal opportunity.